There is evidence that commercial formalinized poliomyelitis vaccine produces a significant degree of protection in those vaccinated against the paralytic form of the disease. However, a number of questions remain to he answered, such as: first, the duration of immunity produced by a killed vaccine, and the necessity and frequency of revaccination; secondly, the fundamental questions about the quality of the immune state resulting from such vaccination as compared with that resulting from natural, inapparent infection. There are indications of qualitative differences in the two types of immunity (natural and artificial) from the observations of Lipson, Robbins, and Woods (1), Gelfand and coworkers (2), and Davis and Melnick (3), that vaccinated associates of frank cases of poliomyelitis when exposed become infected and excrete virus in the feces as readily as do non-vaccinated contacts under similar circumstances. The results to date suggest that although formalinized vaccine produces antibodies and protects against the paralytic disease, it does not protect against the infection of the intestinal tract, possibly because the oropharynx and intestinal tract, never having been exposed, have not been "immunized." The fact that a recently vaccinated individual, largely protected against the paralytic disease, subsequently becomes infected without harm when exposed to virus might be interpreted as a desirable situation in that, by such means, he acquires a natural boost to his immunity. He has then the advantages of some immunity against paralysis provided by the vaccine, and on his own, he acquires an alimentary infection which is believed to be associated with durable immunity.
been developed recently. Ideally, this would eliminate chance in the production of complete and lasting immunity, an important consideration, since the amount of natural exposure likely to occur varies so markedly in different populations with different ways of life, and in some groups chance, in this respect, would be likely to prove undependable indeed. This aspect has been discussed in a recent paper (4) by one of US.
The present report is concerned with observations on a small group whose antibodies had been acquired naturally, or in one instance by vaccination, in which oral immunization against poliomyelitis with a live attenuated strain of poliovirus was tried. The first of such trials with live poliovirus was carried out in 1950 by Koprowski, Jervis, and Norton, who fed a rodent-adapted Type II strain of poliovirus to volunteers who were without Type II antibodies, and followed their excretion of virus and development of neutralizing antibodies (5) . These workers have also induced infection and immune responses in similar trials with a rodent-adapted attenuated Type I strain (6) ; in addition both strains have been fed by Koprowski eta/. to infants possessing passive antibody acquired from their mothers (27) , and by Dane and Dick to infants, children and adults (30) . Attenuated strains of all three types of virus have been developed by manipulating strains in tissue culture (7) (8) (9) (10) , and examples of each type have been fed to humans by Sabin (11) (12) (13) (14) . It is apparent from the work of both Koprowski and Sabin, that infection is readily induced in humans who do not possess antibodies to poliovirnses, using doses as small as 0.001 nil., containing approximately 10,000 tissue culture doses of virus (12) . Virus has also been fed by these workers to individuals with naturally acquired antibodies, some of whom became reinfected (5, (12) (13) (14) . None of the laboratory attenuated strains fed have induced illness and with the exception of one instance (30) none has been found to produce viremia in infected individuals in the course of the induced inapparent infection.
In our trial, an attenuated Type I I I strain of poliovirus was fed to individuals who already possessed Type I H antibodies, either as a result of natural infection, or following vaccination with commercial formalinized Salk vaccine. Our purpose was to determine the ease of infection--or reinfection--in these two types of individuals to see whether a qualitative difference in immunity could be detected; and to determine whether in addition to neutralizing antibody responses, reinfection is accompanied by the appearance of complement-fixing antibodies. We were also concerned with the question as to whether infection would spread to those contacts in close association with the individuals receiving the attenuated poliovirus.
Materials and Methods
The trial was carried out beginning in January, 1956, on the female tuberculosis ward of an institution caring for feeble minded children and adults, t The unit selected was a 15 bed isolation ward consisting of 2 rooms, one with 10 beds, and one with 5. Gown and mask isolation technique was practiced, and all dishes were sterilized on the floor. During the trial all bed linen was sterilized in the basement in a steam sterilizer.
The local staff concerned with patient care consisted of two registered nurses, and a number of trained attendants. These individuals worked only on the tuberculosis ward, and were never transferred to other parts of the institution. A "dean" room was provided for them where outer clothing was changed. Members of the local staff received formalinized vaccine 1 month before the trial was begun.
Subjects.--The entire ward housed 13 patients, all of whom took part in the trial. All but two were ambulatory, and spent most of the day out of bed visiting, and taking their meals in a small dining room. Several of the ambulatory patients were fed at their bedsides for administrative reasons.
The bowel habits of the ambulatory patients were good within the limits of their intelligence. Extra attention to this problem was given to the individuals of low grade intelligence. One of the two bed patients was incontinent. 256  64  256   64  0  256  < 8  256  256  64  256  256  16  16  64  64  0  256  16  64  0  64  64  16 * Vaccinated child, antibody acquired after 2 injections of formalinized vaccine.
The group was divided into two parts, one: those receiving the attenuated virus, numbering 5; and the other the controls, consisting of associates, 8 in number. The ages of members of both groups ranged from 26 to 53, with one exception, a girl of 9. The latter was a case of tuberculous meningitis inactive, with severe brain damage; she had been comatose and tube fed for 3 years. The other 12 had been diagnosed arrested or inactive tuberculosis.
Eleven of the 13 patients had Type III antibodies when their sera were tested several months before the trial was begun. Of the two without such antibodies, one remained as an antibody negative control (S-382), and the other (S-40) received 1 ml. of formalinized vaccine twice, 1 week apart, beginning I month before virus feeding.
The ages and antibody status of the vaccine trial and control groups at the beginning of the procedure is given in Table I .
Vir~s.--An attenuated strain of Type III, Leon KP-34, was generously supplied by Dr.
Albert B. Sabin, of the Children's Hospital Research Foundation, Cincinnati. This strain was isolated in 1937 (15) , adapted to monkey testicular tissue cultures in our laboratory in 1952 (16) and subsequently attenuated in the course of passage through monkey kidney cultures by Sabin (9) . Its attenuation, purity, and loss of capacity to produce paralysis on intracerebral inoculation of monkeys have been described (9, 11, 12) . The virus pool employed in our trial was an aliquot of a lot which had been tested extensively by Sabin and fed by him to 18 volunteers. The titer of the pool was 107.5 TCD60 per ml. when tested in Sabin's laboratory in April, 1955 . Prior to its use by us, the titer of this virus in tissue culture (monkey kidney cells) was determined in half log dilutions by the tube method, using 7~ 75 7 7 111 125 * The numbers stand for the number of specimens desired from the five individuals in the vaccine trial and the eight members of the control group.
:~ One control died.
6 tubes per dilution, and by the plaque method as modified for bottles by Hsinng and Melnick (17) . In tubes, the result was I0 TM TCD~ per ml.; by plaque count 2 it was 10 7.6 plaqueforming units (PFU) per ml.
Virus Feeding Schedule.--Based on Sabin's experience (11, 12) two dosages of virus were used: 3 individuals received 10 +.~ TCD~ of virus and 2 individuals received l& 3 TCD+0. The virus was added to 4 to 6 ml. milk and this material was fed in a tablespoon at 11:00 a.m., January 10, 1956, several hours after breakfast, and preceding lunch by one-half hour. One individual, S-40, who was comatose, received the virus by stomach tube; in addition, her throat was swabbed with the virus-milk mixture.
We are indebted to Dr. G. D. Hsiung for carrying out this titration. Table II shows the schedule set up for the collection of: 1, blood specimens for virus testing and for antibody determinations; 2, throat swabs; and 3, stools, for virus isolation. Except for minor deviations, the schedule was adhered to closely. Blood specimens were collected in vacuum syringes, allowed to clot, and separated either on the day of collection, or on the following morning if blood was drawn late in the afternoon. Throat swabs were placed in 1 ml. of sterile saline; both stools mad throat swabs were frozen immediately after collection and kept frozen until tested.
Collection and Preparation o/Specimens.--
Throat swabs were extracted in a total of 2 ml. of saline, containing 500/~g. penicillin and 500 #g. streptomycin. Before inoculation into tissue culture tubes the extracts were spun at 3000 I~.P.M. for 15 minutes, the sediment being discarded.
Stool specimens were collected according to the schedule in Table II . They were immediately stored in the frozen state and were subsequently prepared and inoculated in the routine manner used in this laboratory (18) . After thawing, 5 gin. were weighed out, and mixed with 27 ml. of sterile water, in a pyrex bottle. The suspension was shaken for 1 hour on a mechanical shaker, then centrifuged at 4000 l~.P.~, for 1 hour. To the supernatant fluid which constituted the inoculum, 500/~g. of penicillin and 500/~g. of streptomycin per ml. was added.
Testing of Specimens for
Virus.--Culture tubes containing trypsinized monolayer monkey kidney tissue grown in a medium containing 0.5 per cent ]actalbumin hydrolysate, 2 per cent calf serum, and 97.5 per cent Hank's salt solution were used throughout. Sera were inoculated in 0.1 ml. amounts, into 10 tubes per specimen; mad throat swabs, 0.2 ml. into 3 tubes per specimen. Tubes to be inoculated with stool specimens were drained of media, and 1 ml. of the clarified stool suspension was added; after 1 hour's incubation at room temperature the inoculum was removed from the culture tubes and replaced with 1 ml. of media. Six tubes were used per specimen.
All tubes were observed for 12 days; those showing degeneration were harvested mad passed. If, after 12 days, the kidney tissue appeared normal, a blind passage was made to 4 tubes, which in turn were observed for 12 days.
All isolates were identified in neutralization tests set up against the 3 types of poliovirus as well as a pool of the 3 types (18). Each positive specimen was titrated in log dilutions and the TCso per ml. of throat swabs, and per gram of stool, were calculated by the Reed-Muench formula.
Monkey Virulence Tests on Virus Excreted by Infected Subjeas.--Virus strains isolated
from two individuals were tested for their ability to produce paralysis in monkeys on intracerebral or intraspinal injection, to determine whether human passage had altered the neurotropism of the strain fed. Virus from the last positive stool was selected for this kind of test in each instance. This represented in the ease of subject S-9, the stool collected on day 13, which had a titer of 10 x~ per gram, and for subject S-40, the stool collected on day 41, titering 10 *.° per gin. The two isolates were given a second tissue culture passage, and the harvest was titered in tissue culture in the usual manner described above. At the same time log dilutions were inoculated intracerebrally or intraspinally into three monkeys per dilution.
Both rkesus (Maraca mulatta) and cynomologus (Maraca cynomolgus) monkeys were used.
The animals were followed for 4 weeks and sacrificed at that time, or earlier, if paralysis occurred. Histological sections from the CNS of all animals were examined for lesions of poliomyelitis.
Serological Tests.--Sera were inactivated at 56°C. for 30 minutes prior to testing for antibodies. Serial specimens from each individual were run in the same test.
Neutralization tests were carried out by the pH colorimetric method as modified by Melnick and Opton (19) , using disposable plastic panels, and versenized second passage monkey kidney cells. Sera were tested in a preliminary screening at 1:4, 1:8, 1:16, 1:64, 1:256, and 1:1024, using 1 cup per dilution. Most specimens from those individuals who became infected were subsequently titrated over a wider range of 2-fold dilutions, using 3 cups per dilution.
Complement fixation tests (designated hereafter as CF) were set up on plastic plates, using the method of Fulton and Dumbell (20) as modified by Black and Melnick (21) . Tissue culture-gown antigens of the three types of poliovirus were used; in some tests both unheated and heated (56 ° for 30 minutes) antigens were used, but since there were no differences detected between the two with the antigens then in use, only heated preparations were used in the later tests. RESULTS
Four of the five individuals fed virus developed inapparent infection, as evidenced by virus excretion and antibody responses. The results for each individual including the amounts of virus excreted are given in detail in the accompanying tables, I I I to VII. At no time did any of the infected subjects or controls have any symptoms or signs of illness suggestive of poliomyelitis. None showed any significant temperature rises.
None of the control subjects who were living in the same ward and thus were exposed to those with inapparent infection became infected. Their throat swabs and stools were repeatedly negative for virus and none showed any antibody shift. The one control without Type I I I antibodies (S-382) did not acquire them. Another control ($-1) died from a malignant neoplasm 41 days after the experiment was begun. (Table III) . The prefeeding Type I I I neutralizing antibody titer of this individual was 1:64. Virus was not detected in her throat, but was present in the stools from the 2nd through the 7th day. She showed a rise in neutralizing antibodies to Type I I I on the 10th day; CF antibodies rose on the 14th day, both to Types I I and III.
L Results with the Smaller Dose of Virus (104.STCDso).--There
The second individual, No. S-17 (Table IV) , failed to become infected. Her Type I I I neutralizing antibody titer was 16 before feeding, and remained at that level. No CF antibodies appeared.
The one individual who acquired Type I I I antibodies as a result of vaccination with forraalini~.ed vaccine (S-40) became infected after feeding and excreted
virus in the stool from the 3rd through the 41st day; the next stool tested was excreted on day 63, and was negative (Table V) . Virus was not recovered from the troat or blood of this individual. Neutralizing antibodies 8 against Types I I and I I I rose between the 10th and 21st day. CF antibodies to all three types appeared on day 10. * Prior to receiving formalinized vaccine the neutralizing antibody pattern on this child was 0, < 8, < 4, for the 3 types; on the day of feeding (1 month after vaccination) it was 0, 64, 16. Table, and in Tables V to VII isolation from throat swabs is expressed as log TCD~0 per hal., and isolation from stools is expressed as log TCD~0 per gin.
I I . Results with the Larger Dose of Virus (107.STCD~o).--Both individuals
who were fed the larger dose became infected; both excreted virus in the throat and in the feces.
No. S-21 (see Table VI ) whose prefeeding Type I I I titer was 1:64 had virus in the throat from the 4th through the 6th day, and in the stool from the 1st through the 7th day. Type I I I neutralizing antibodies rose on the 10th No. S-9 (see Table VII ), whose prefeeding Type I I I antibody level was 8, excreted virus in the throat from the 2nd through the 6th day, and in the 
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Blood Throat Stool -..._I_I. stool from the 4th through the 13th day. Neutralizing antibodies to all three types rose sharply on the 10th day, and were still high on the 63rd day. T h e C F response was insignificant: a titer of 1 "4 (with an avidity of 6) was present on the 14th and 21st days, and then disappeared.
I I I . Monkey Virulence Tests on Type I I I Strain Isolated from Stools.--
Virus derived from the last positive stool specimen of volunteers S-9 and S-40, collected 13 and 41 days respectively after feeding, were tested for paralyto- genic capacity by inoculation of rhesus and cynomolgus monkeys intracerebrally or intraspinally. Tests on the attenuated KP34 strain of Type I I I which was fed to these individuals had previously been carried out by Sabin et al. (9) , who reported that the virus failed to produce paralysis in cynomolgus monkeys on intracerebral injection, even when 107.2TCD~0 were given; he found that none of 28 monkeys receiving intracerebral dosages ranging from 101.2 to 107.2TCDs0 (4 animals per dilution) developed paralysis or demonstrable CNS lesions. Subsequently, Sabin found on further tests with the KP34 strain that a certain proportion of monkeys inoculated intracerebrally with large amounts Tables  V I I I and IX, and in Table X , these are compared with Sabin's tests on the virus fed. I n testing the strains isolated from the stools, second tissue culture passage was inoculated into monkeys. I n each instance, the TCDs0 was 10 ~.5 per ml. I n the case of virus isolated from volunteer S-9 (Table V I Giant ceils at inoculation site * The titer of the TC fluid was i0 ~-5 per ml. Monkeys were inoculated with 0.6 ml. intracerebrally, or 0.1 ml. intraspinally. (TCDso), dose of virus inoculated.
Incomplete test.
intraspinally inoculated animals receiving the same material, one of 3 inoculated with 102.STCD60 developed paralysis, and another had lesions in the lumbar cord without CNS signs. Similar results were obtained with virus derived from the stools of subject S-40 (Table IX) . One of 2 animals receiving 105.STCDso intracerebrally became paralyzed, and one of 3 given 104.STCD~0 showed lesions at all levels of the cord but gave no evidence of muscle weakness or other CNS signs. The 104.5-TCD60 intraspinally induced paralysis in 2 of 3 animals; 10a.STCDs0 failed to produce paralysis but produced lesions locally at the site of the injection and on the contralateral side of the lumbar cord in one of 3 animals. :~ Denominator, number tested; numerator number with lesions and~or paralysis. § Number in parentheses indicates number paralyzed. ti When present, lesions found in lumbar and cervical cord in all but two animals, in which only lumbar level involved.
Although in both instances the excreted virus showed some increase in virulence by the intracerebral test (see Table X ), nevertheless it remained a relatively attenuated strain, since approximately 100,000 TCDs0 were required to produce paralysis in intercerebrally inoculated animals.
Somewhat different results, however, were obtained when the excreted virus from the same two infected individuals was tested by the "in vitro plaque virulence test" of Dulbecco and Vogt as given in reference 22 and as modified for use in bottles by Hsiung and Melnick (17, 23) in that the virus from one individual, S-40, behaved as a virulent strain. This test depends on the difference between virulent a n d attenuated strains in rate of growth and size of plaques in high and low concentrations of bicarbonate ion: the attenuated strains grow more slowly and produce relatively few plaques at low bicarbonate concentrations, whereas virulent strains produce approximately equal numbers of plaques at both low and high bicarbonate concentrations. The virus isolated from S-9, 13 days after virus feeding, behaved in the manner characteristic for attenuated strains, while that isolated from S-40, some 6 weeks after virus feeding, behaved in the manner characteristic of virulent strains. The following table lists the efficiency of plating virus as present in the second tissue culture passage from both patients and in addition directly from the stool of one. Efficiency of plating refers to the ratio of PFU per milliliter in bottles containing 0.075 gm. per cent of NaHCO3 in the overlay, to that in bottles containing 0.45 gm. per cent NaHCO3: 
DISCUSSION
This trial confirms the observation that it is possible to reinfect individuals who posses homotypic antibodies acquired through previous natural infection. Thus, three of four whose natural Type I I I antibody titer ranged from 8 to 64 became reinfected. In addition, one child whose Type I I I antibodies were acquired by vaccination, also became infected. This confirms similar, recently published findings by Sabin (13, 14) , and the clinical and field observations already quoted (1-3). Although four individuals in our trial were infected and excreted virus, there was no indication of any spread of the agent to close contacts, all of whom were adults, either those with antibodies, or the one individual who was antibody negative.
The results in artificially infected humans follow a pattern similar to that observed in chimpanzees in this laboratory (24) and by Howe, Bodian, and Morgan (25) . Chimpanzees are readily infected on first exposure to poliovirus. On being challenged orally with a strain of which they had previously been carriers, homotypic immunity could be demonstrated in most animals, but in a small percentage (8 per cent) reinfection occurred in our experiments. In contrast, challenge with an heterotypic strain produced reinfection in 70 per cent of animals.
In the earliest report of Koprowski et al. (5) on the oral infection of human volunteers with an attenuated Type II virus, three persons with naturally acquired Type II antibodies at levels of 1:94 to 1:900 were fed doses ranging from 10 s'l to 105"s MLDso.
Two of the three were found to be excreting virus on day 5 and day 23 respectively after feeding, but neither of these developed any increase in neutralizing antibodies following virus excretion. The third individual neither excreted virus nor showed any change in antibody status.
In studies reported by Sabin (12) , all four adults who had low level naturally acquired neutralizing antibodies prior to ingestion of large amounts of virus, excreted virus and all developed rises in titer; two others, fed smaller doses (104"~ TCD~0) failed to develop alimentary infection or antibody rise, even though they possessed only traces of homotypic antibody before virus feeding.
Our results are unlike Koprowski's but parallel those of Sabin (12) in that all individuals in whom virus multiplication occurred showed an increase in neutralizing antibody fiter. In our trial, those fed the larger dose (107"5 TCDm) all became infected, whereas only one of two with natural antibodies fed the smaller dose (104'5 TCD~) did so. Furthermore, the one who resisted reinfection with the lower dosage had a lower prefeeding level of homotypic antibody (1:16) than the one who became infected (1:64), suggesting that the titer of antibody is not the only factor concerned in preventing reinfection (12) (13) (14) .
The amounts of virus excreted in the four infected subjects were similar, ranging from 10 l's to 104.6 TCDm per gram of stool. There was a difference, however, in the duration of excretion: the 3 with naturally acquired antibodies passed virus for a total of from 7 to 13 days, while the child whose antibodies had been acquired through vacckuation, continued to excrete the agent until some time between the 41st and 63rd postfeeding day. Thus in this single observation, the excretion of virus following infection in a child with Salk vaccine-induced antibodies continued for at least 6 weeks, a duration comparable to that seen in natural primary infection (26) , while those with similar levels of antibody, acquired naturally, excreted virus for a brief period of 7 to 13 days only. Long duration of virus excretion in infants following infection induced in the presence of passive--maternally acquired--antibody has recently been described by Koprowski et al. (27) .
The absence of viremia in the experimental subjects, all of whom had homologous antibody before being fed, is not surprising. Neither Koprowski (5, 6) nor have detected vlremia in individuals fed laboratory attenuated strains of virus even though they had no nomotypic antibody at the time of feeding. In fact, on the basis of experience to date, failure to induce viremia might turn out to be an essential characteristic in any strain labeled "attenuated".
The antibody responses of the four infected individuals were variable and not related to dosage, duration of excretion, presence or absence of virus in the throat. Of the three with naturally acquired prefeeding neutralizing antibody, all showed sharp and persistent (over 84 days) neutralizing antibody rises; the heterotypic responses were slighter and more transient in two (S-8 and S-21) and high and persistent in the other (S-9). The only person of these three who developed an appreciable CF response (S-8) already had CF antibodies at the time of virus feeding, whether from a recent poliovirus infection, or infection with an antigenically related agent, is not known. Of the other two individuals only one showed a transient CF response, the other none at all, although both had vigorous neutralizing antibody reactions. Whether minimal or absent CF response is a characteristic pattern on reinfection cannot be determined until more subjects are studied.
The child with formalinized vaccine-induced neutralizing antibodies had the smallest homotypic neutralizing antibody response, but was the only one with a fourfold rise in CF antibodies, both homo-and heterotypic.
It has been suggested that persons with previous antibody, whether naturally or artificially acquired, will respond to reinfection with a more rapid rise in antibody than do those experiencing a primary infection (28) . This was not the case in the four individuals studied in the present experiments: the neutralizing and CF antibodies appeared at about 7 to 10 days, the same time interval at which they have appeared in primary experimental infections (5, 12) .
The results of tests for virulence on recovered virus (Tables VIII and IX) indicate that a higher degree of neurotropism was present in the virus being excreted than in the material ingested by the volunteers. The KP34 strain, when tested by Sabin et al. (9, 11, 12) failed to produce paralysis in cynomologus monkeys on intracerebral injection, even when 107.~ TCDs0 were given; he found that none of 28 monkeys receiving intracerebral dosages ranging from 101"2 to 10 ~-~ TCDs0 (4 animals per dilution) developed paralysis or demonstrable CNS lesions. In contrast, the virus excreted by 2 of our patients, produced paralysis in both animals given a dosage of 105.8 TCDs0, and in one instance, lesions in one of two animals given 104.8 TCD60. A likely explanation of this increased virulence is that the KP34 virus strain fed, represented a mixture of neurotropic and non-neurotropic particles, despite its "purification" by the terminal dilution method. This has recently been shown by Sabin (14) to be the case: when the strain was plated by the plaque method (29) both neurotropic and non-neurotropic colonies were found. In terms of our experiment, the 2nd tissue culture passage of the virus excreted apparently contained relatively more neurotropic particles than did the ingested virus. The question as to whether passage in humans had resulted in the emergence of more neurotropic particles, or whether it was the two subsequent passages in tissue culture which had favored their appearance, cannot be answered as far as monkey virulence is concerned, since the titer of virus in the stools was too low to allow adequate direct test.
The results of the "in vitro plaque virulence test" agreed with the monkey virulence tests in the one instance, but was at variance with it in the other. It is not possible to assess the significance of this observation until more is known of the correlation of results by the two different methods. However, Hsiu~ag and Melnick have obtained data with other strains of poliovirus which gave a positive in vitro test for virulence (high efficiency of plating at low bicarbonate concentration), but which failed to produce disease when 1000 to 100,000 PFU were inoculated intracerebrally into rh,sus monkeys (23) .
This observation on apparent increase in virulence raises the old question as to whether it is possible to demonstrate a change, i. e. an enhancement or degradation in the virulence of microorganisms, during the course of a single clinical infection. It would seem that future work on a large number of subjects might give valuable results relative to this point.
SUMMARY
Four of five individuals possessing homotypic antibody in titers of 8 to 64 were infected on being fed Type III (Leon KP-34) poliovirus attenuated by Sabin by passage through tissue culture.
None of the infected subjects or controls showed any evidence of illness which could be attributed to virus infection.
There was no evidence of spread of infection to any of the control adult wardmates of the experimental subjects, although the two groups were in close contact: none of the controls excreted virus, none showed any antibody shift. One control who had no Type III antibodies at the start of the experiment was still antibody-negative on the 63rd day of the experiment.
Three of the four individuals who became infected had naturally acquiredType III antibodies; the other had antibodies induced by formalinized vaccine.
Virus excretion in the stool was of short duration (7 to 13 days) in the three with natural antibodies, and lasted at least 6 weeks after feeding in the vaccinated child.
Virus in the throat was detected only in the two persons receiving the larger virus dose (107.5 TCDs0). In them it was present in small amounts between the 2nd and 6th day after feeding.
No virus was detected in the blood of any of the infected individuals. The antibody responses of the four infected individuals were variable. There was no clear correlation with virus dosage, amount of virus excretion in the stools, or presence of virusin the throat. Only the child whose neutralizing antibodies were "Salk" vaccine induced showed a marked CF response.
The virus excreted by two of the individuals who became infected, as tested in the 2nd tissue culture passage by monkey inoculation, was slightly more neurotropic than the virus which was ingested. Virus excreted by one of these individuals behaved as a virulent strain when tested by the in vitro plaque virulence test, while that isolated from the other had the characteristics of an attenuated strain in this test. 
